Kymera Therapeutics has entered into a partnership with Gilead Sciences involving an option and license deal worth up to $750 million to develop and commercialize a class of cancer drugs focused on molecular glue degraders targeting CDK2. Gilead provided $85 million upfront as part of the agreement. This deal comes as Kymera faces a setback with its collaboration with Sanofi, which has decided to discontinue its lead IRAK4 degrader candidate KT-474 and instead focus on a follow-up candidate, KT-485, expected to enter first-in-human trials in 2026. Kymera is also advancing a novel target, STAT6, which is fully owned by the company and showing early pharmacodynamic signals. The partnership with Gilead is seen as a vote of confidence in the potential of molecular glue degraders to unlock new cancer therapies. The deal provides Kymera with non-dilutive funding and a reset of its lead asset strategy amid the changes in its Sanofi collaboration.